Kardigan, a biotechnology company focused on redefining cardiovascular drug development, announced the successful closing of a $254 million Series B financing round. The funding round featured participation from new investors, including Fidelity Management & Research Company and accounts advised by T. Rowe Price Investment Management, alongside renewed support from long-time backers ARCH Venture Partners and Sequoia Heritage.
The funding will advance the company’s late-stage clinical programs targeting specific forms of dilated cardiomyopathy (DCM), calcific aortic valve stenosis (CAVS), and acute severe hypertension (ASH): three life-threatening conditions that currently lack effective treatments.
The funding reinforces Kardigan’s strategic roadmap as it advances toward multiple data readouts beginning in 2026, positioning the company to play a defining role in the next generation of cardiovascular therapeutics.
Kardigan’s approach is built on the principle of “cardiac intelligence”—using advanced data science and precision medicine to understand the biological roots of cardiovascular disease. By combining molecular insights with cutting-edge clinical research, the company aims to move beyond symptom management and deliver functional cures for patients.
The company’s three leading programs represent distinct and complementary strategies for addressing key cardiovascular diseases:
- Danicamtiv – A cardiac myosin activator designed to treat genetic DCM caused by sarcomeric variants.
- Tonlamarsen – An angiotensinogen-targeted bridging therapy expected to interrupt the pathological cycle of ASH.
- Ataciguat, a once-daily, oral soluble guanylate cyclase (sGC) activator positioned as a potential first-in-class treatment for CAVS and a therapeutic alternative to “watchful waiting.”
Each program embodies Kardigan’s commitment to tackling cardiovascular diseases at their biological source, rather than managing the downstream symptoms that often lead to lifelong treatment dependence. The company’s pipeline underscores a broader shift toward precision-based cardiology, emphasizing individualized therapies guided by genetic and molecular data.
The Series B funding will support ongoing and planned clinical trials across all three programs while scaling the company’s development capabilities and operational infrastructure.
By advancing these candidates simultaneously, Kardigan seeks to deliver multiple medicines in parallel—a departure from traditional, sequential drug development models.
Founded on the belief that heart disease can become preventable and curable, Kardigan’s leadership team combines deep scientific expertise with a capital-efficient model designed to advance discovery and development. The company’s headquarters in South San Francisco and Princeton, New Jersey, serve as innovation hubs for its integrated research and data platforms.
KEY QUOTE:
“The support of our new and existing investors affirms the strength of Kardigan’s differentiated scientific strategy and bold vision to make cardiovascular disease preventable, curable, and no longer the leading cause of death in the world. We are building a different, capital-efficient company powered by science, data, and technology. With cardiac intelligence, Kardigan is advancing an unparalleled understanding of the heart, redefining the model for therapeutic innovation — one designed to address cardiovascular diseases at their source rather than just manage symptoms.”
Tassos Gianakakos, Co-Founder, Chief Executive Officer, and Chair of Kardigan
